{"gene":"TNFSF15","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2002,"finding":"TL1A (TNFSF15) is a ligand for death receptor DR3 and decoy receptor TR6/DcR3. Binding to DR3 on T cells induces NF-κB activation and apoptosis in DR3-expressing cell lines, and costimulates T cells to increase IL-2 responsiveness and proinflammatory cytokine secretion. TR6-Fc antagonizes these signaling events.","method":"Receptor-ligand binding assays, NF-κB reporter assays, apoptosis assays, T cell functional assays in vitro and in vivo","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1–2 — foundational receptor identification with multiple orthogonal functional assays, highly cited original discovery paper","pmids":["11911831"],"is_preprint":false},{"year":2003,"finding":"TL1A-DR3 interaction in TF-1 cells induces formation of a signaling complex containing TRADD, TRAF2, and RIP, and activates NF-κB and ERK/JNK/p38 MAPK pathways. NF-κB activation prevents DR3-mediated apoptosis via upregulation of c-IAP2; siRNA knockdown of c-IAP2 sensitizes cells to TL1A-induced apoptosis.","method":"Co-immunoprecipitation of signaling complex, NF-κB reporter assays, MAPK inhibitor studies, RNA interference, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including Co-IP, RNAi, and pathway inhibitor rescue in a single study","pmids":["12882979"],"is_preprint":false},{"year":2004,"finding":"TL1A synergizes with IL-12 and IL-18 to augment IFN-γ production in human peripheral blood T cells and NK cells. DR3 expression is differentially regulated by IL-12/IL-18 in T cells versus NK cells.","method":"Cytokine stimulation assays, intracellular cytokine staining, agonistic anti-DR3 mAb experiments, flow cytometry for DR3 expression","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean functional assays with agonist antibody confirmation, replicated across T cell and NK cell populations","pmids":["15153521"],"is_preprint":false},{"year":2004,"finding":"DcR3 (decoy receptor 3) induces angiogenesis in endothelial cells by neutralizing TL1A, which itself has angiostatic action on endothelial cells expressing DR3. Anti-TL1A and anti-DR3 antibodies mimic DcR3 pro-angiogenic effects, and TL1A promotes HUVEC apoptosis.","method":"Endothelial cell proliferation, migration, and tube formation assays; in vivo neovascularization; neutralizing antibody experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal functional assays with antibody-based pathway dissection","pmids":["14871847"],"is_preprint":false},{"year":2007,"finding":"TL1A expression in human monocytes and monocyte-derived dendritic cells is strongly induced by FcγR stimulation (immune complexes), but not by TLR agonists. FcγR-induced TL1A appears on the cell surface and in culture medium and enhances T cell responses.","method":"TLR and FcγR agonist stimulation, TL1A mRNA and protein detection, surface flow cytometry, T cell co-culture assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — specific pathway identified with multiple stimuli tested across multiple cell types","pmids":["17371957"],"is_preprint":false},{"year":2008,"finding":"TL1A-DR3 interaction promotes proliferation and cytokine production from effector Th17 cells. TL1A-deficient dendritic cells have reduced capacity to support Th17 differentiation and proliferation, and TL1A-/- animals display decreased clinical severity in EAE.","method":"TL1A knockout mouse generation, EAE model, Th17 differentiation assays, DR3 expression profiling on Th17 cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with defined cellular phenotype, in vivo and in vitro confirmation","pmids":["18411337"],"is_preprint":false},{"year":2008,"finding":"TL1A upregulates both IFN-γ from Th1 cells and IL-17 from Th17 cells in gut-associated lymphoid tissue CD4+ T cells, synergistically with IL-12 and IL-23 respectively. Anti-TL1A antibody prevents and attenuates chronic DSS colitis.","method":"DSS chronic colitis model, cytokine measurement, anti-TL1A neutralizing antibody treatment, T-cell transfer colitis model","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — in vivo neutralization with defined cytokine readouts in two murine colitis models","pmids":["18598698"],"is_preprint":false},{"year":2009,"finding":"Crystal structure of the human TL1A extracellular domain at 2.5 Å resolution reveals a jelly-roll fold typical of the TNF superfamily. Mutagenesis and biochemical characterization define the binding interface with DcR3 and DR3, showing that TL1A-DcR3 interaction differs from other characterized TNF ligand/receptor complexes.","method":"X-ray crystallography, mutagenesis, biochemical binding assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis and biochemical validation in a single study","pmids":["19522538"],"is_preprint":false},{"year":2009,"finding":"VEGI/TNFSF15 inhibits differentiation of endothelial progenitor cells (EPCs) from bone marrow Sca1+ cells. VEGI induces apoptosis of differentiated EPCs but not early-stage EPCs; this is mediated by DR3, which is expressed only on differentiated EPCs. Neutralizing antibodies to DR3 inhibit VEGI-induced apoptosis.","method":"EPC differentiation assays, flow cytometry for endothelial markers, apoptosis assays, DR3 neutralizing antibody experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway defined with receptor-specific neutralization and stage-specific phenotyping","pmids":["19329781"],"is_preprint":false},{"year":2009,"finding":"Multiple bacterial species (gram-negative, gram-positive, anaerobes) induce TL1A expression in human APCs (monocytes and DCs) via the TLR signaling pathway; this induction is inhibited by downstream blockade of p38 MAPK and NF-κB activation. Bacterially induced TL1A augments IFN-γ production by CD4+ T cells.","method":"Bacterial stimulation of human monocytes/DCs, TL1A mRNA and protein measurement, kinase inhibitor studies, T cell co-culture","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway dissection with inhibitors across multiple bacterial species and cell types","pmids":["19839006"],"is_preprint":false},{"year":2010,"finding":"TL1A drives IL-13-dependent small intestinal inflammation when constitutively expressed in T cells or dendritic cells in transgenic mice. TL1A-DR3 interactions are necessary and sufficient for T cell-dependent IBD, and TL1A suppresses inducible Treg generation.","method":"Transgenic mouse generation (T cell and DC-specific TL1A expression), TNBS colitis model with TL1A-DR3 blockade, cytokine and histological analysis","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 — transgenic mouse phenotype with ligand-receptor blockade rescue, multiple disease models","pmids":["20980995"],"is_preprint":false},{"year":2010,"finding":"In naive human CD4+ T cells, TL1A via DR3 inhibits Th17 generation, while in committed Th17 cells it supports maintenance of IL-17A expression and proliferation under suboptimal TCR activation. DR3 is induced rapidly upon T cell activation and expressed prominently on IL-17-secreting T cells.","method":"Flow cytometry for DR3, Th17 differentiation assays, neutralizing antibodies, DR3-deficient mouse T cells, cytokine measurement","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — genetic KO cells and neutralizing antibodies with multiple orthogonal readouts","pmids":["20826539"],"is_preprint":false},{"year":2010,"finding":"Membrane-bound TL1A (TL1A-M) can bind DR3 through cell-cell contact and induce IFN-γ secretion from IL-12/IL-18-primed CD4+ T cells, demonstrating functional activity of the membrane form distinct from soluble TL1A.","method":"TL1A-M expression in HEK-293 cells, DR3-Fc binding assay, T cell co-culture with IFN-γ measurement, anti-TL1A antibody blocking","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — direct membrane-bound functional assay but single lab, single study","pmids":["20403353"],"is_preprint":false},{"year":2011,"finding":"AMPK activation upregulates LITAF transcription, and LITAF in turn drives TNFSF15 (TL1A) expression by binding to a specific promoter sequence. TNFSF15 inhibits proliferation of prostate cancer cells and endothelial cells, and intratumoral injection reduces tumor size and blood vessel number in vivo.","method":"shRNA knockdown, dominant-negative AMPK mutant, promoter binding assay, cell proliferation assays, xenograft tumor model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods in single lab defining AMPK-LITAF-TNFSF15 axis","pmids":["21217782"],"is_preprint":false},{"year":2013,"finding":"TL1A drives allergic pathology through group 2 innate lymphoid cells (ILC2s), which express surface DR3 and produce IL-13 and type 2 cytokines in response to TL1A. DR3 is required for ILC2 expansion in T cell-dependent and -independent allergic disease models, independent of IL-25 or IL-33.","method":"Constitutive TL1A transgenic mice, DR3-deficient mice, ILC2 isolation and functional assays, allergic lung disease models","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO and transgenic models with defined cellular phenotype across multiple models","pmids":["24368564"],"is_preprint":false},{"year":2013,"finding":"Soluble TL1A-Ig fusion protein mediates rapid in vivo expansion of FoxP3+ regulatory T cells (Tregs) to 30-35% of all CD4+ T cells. Treg expansion requires TCR engagement with MHC class II and is protective against allergic lung inflammation. TL1A-Ig also blocks de novo inducible Treg generation and attenuates Treg suppressive function.","method":"TL1A-Ig fusion protein generation, in vivo Treg expansion, TCR-MHC blockade experiments, allergic lung inflammation model","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — pharmacological and genetic approaches with defined in vivo cellular and functional outcomes","pmids":["23319737"],"is_preprint":false},{"year":2013,"finding":"TL1A signaling via DR3 on primary intestinal myofibroblasts directly increases collagen and IL-31Ra expression. Neutralizing TL1A antibody or DR3 deletion reduces fibroblast and myofibroblast numbers and reverses established colonic fibrosis.","method":"Primary myofibroblast culture, TL1A stimulation, anti-TL1A neutralizing antibody, DR3 knockout mice, collagen quantification","journal":"Mucosal immunology","confidence":"High","confidence_rationale":"Tier 2 — direct cell stimulation, genetic KO, and antibody neutralization with multiple fibrosis readouts","pmids":["24850426"],"is_preprint":false},{"year":2013,"finding":"TL1A inhibits proliferation of activated human B cells that express DR3 following BCR polyclonal stimulation, without affecting B-cell survival.","method":"B cell DR3 expression by flow cytometry and immunofluorescence, B cell proliferation assays with TL1A treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2–3 — novel cell type identified with direct functional assay, single lab","pmids":["23565196"],"is_preprint":false},{"year":2013,"finding":"TNFRSF25 (DR3) ligation by TL1A recruits TRAF2 and TRADD in primary T cells and activates NF-κB and PI3K/Akt pathways in a TCR- and IL-2R-dependent manner, leading to constitutive proliferation of CD4+FoxP3+ Tregs through tonic self-antigen exposure.","method":"Primary T cell signaling studies, pathway inhibitor assays, Treg proliferation assays","journal":"Immunologic research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic signaling dissection in primary cells, single review/research lab synthesis","pmids":["24242819"],"is_preprint":false},{"year":2013,"finding":"TL1A KO mice have ameliorated collagen-induced arthritis with reduced anti-collagen antibody titers. Plasma cells (but not B cells) express high levels of DR3 and are direct targets of TL1A; TL1A promotes plasma cell survival and antibody production.","method":"TL1A KO mouse generation, CIA model, serum antibody ELISA, DR3 expression on plasma cells by flow cytometry, plasma cell survival assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with in vivo disease model and mechanistic identification of novel TL1A target cell type","pmids":["24140642"],"is_preprint":false},{"year":2014,"finding":"TNFSF15:DR3 interactions in human macrophages amplify PRR-induced MAPK/NF-κB/PI3K signaling and cytokine secretion. TACE-induced cleavage of membrane TNFSF15 produces soluble TNFSF15, which then drives TRADD/FADD/MALT-1- and caspase-8-mediated autocrine IL-1 secretion. The rs6478108 disease-risk allele increases TNFSF15 expression, leading to a gain-of-function in PRR signaling.","method":"Human macrophage stimulation, TACE inhibitors, caspase-8 inhibitors, siRNA knockdown, TRADD/FADD pathway analysis, risk allele genotyping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal mechanistic approaches including inhibitors, siRNA, and genetic variant functional analysis","pmids":["25197060"],"is_preprint":false},{"year":2014,"finding":"DR3 mediates TNFSF15-induced apoptosis in endothelial cells; DR3 siRNA knockdown confers resistance to TNFSF15-induced apoptosis and is associated with increased ERK1/2 MAPK activity and upregulation of anti-apoptotic c-FLIP and Bcl-2. TNFα-induced upregulation of TNFSF15 is partly responsible for TNFα-induced endothelial cell apoptosis.","method":"siRNA knockdown of DR3, apoptosis assays, western blot for c-FLIP and Bcl-2, ERK1/2 activity measurement, TNFSF15 neutralizing antibody","journal":"The international journal of biochemistry & cell biology","confidence":"High","confidence_rationale":"Tier 2 — siRNA-based receptor identification with mechanistic downstream pathway analysis","pmids":["25161149"],"is_preprint":false},{"year":2015,"finding":"Soluble TL1A trimers are sufficient to strongly activate DR3-associated pro- and anti-apoptotic signaling pathways without secondary ligand oligomerization, unlike TRAIL death receptors. TL1A-DR3 interaction affinity was measured in a cell-based system, and TL1A induces DR3 internalization.","method":"Recombinant soluble TL1A production, cell-based affinity measurement, DR3 signaling assays, receptor internalization assays","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1–2 — biochemical characterization of ligand requirements with multiple signaling readouts","pmids":["26509650"],"is_preprint":false},{"year":2015,"finding":"The PBC-susceptibility allele at rs4979462 in the TNFSF15 locus generates a novel NF-1 binding site that enhances TNFSF15 promoter activity and increases endogenous TNFSF15 protein and mRNA expression.","method":"Luciferase reporter assay, electrophoretic mobility shift assay (EMSA), super-shift assay, endogenous mRNA/protein quantification by genotype","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 1–2 — functional variant mechanism defined with multiple orthogonal molecular methods","pmids":["25899471"],"is_preprint":false},{"year":2013,"finding":"TNFSF15 inhibits vasculogenesis by simultaneously promoting ubiquitin-mediated degradation of membrane VEGFR1 (mFlt1) and upregulating soluble VEGFR1 (sFlt1) in EPCs, disrupting VEGF/PlGF-induced eNOS and MAPK p38 activation. TNFSF15 also promotes alternative Flt1 pre-mRNA splicing toward sFlt1 by downregulating Jmjd6.","method":"EPC culture assays, Matrigel implant in vivo model, siRNA for DR3, Akt/ubiquitin pathway analysis, splicing factor (Jmjd6) knockdown","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic pathway defined in vitro and in vivo with multiple orthogonal approaches","pmids":["23918400"],"is_preprint":false},{"year":2016,"finding":"TNFSF15 suppresses VEGF production in endothelial cells by activating the JNK signaling pathway and transcription factor GATA3, which upregulates miR-29b that targets the 3'-UTR of VEGF transcript. siRNA against DR3 or neutralizing antibody against TNFSF15 inhibits miR-29b expression and restores VEGF production.","method":"siRNA knockdown, JNK inhibitor (SP600125), miR-29b measurement, 3'-UTR reporter assays, GATA3 siRNA","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic pathway (TNFSF15→JNK→GATA3→miR-29b→VEGF) defined with multiple orthogonal genetic and pharmacological tools","pmids":["27589684"],"is_preprint":false},{"year":2017,"finding":"HDX-MS combined with computational modeling revealed that an anti-TL1A monoclonal antibody (mAb1) binds a discontinuous epitope on TL1A spanning the predicted TL1A-DR3 interaction interface, including residue R32 critical for DR3 but not DcR3 binding.","method":"Hydrogen/deuterium exchange mass spectrometry, electron-transfer dissociation MS, SASA analysis, computational modeling","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 1 — structural/biochemical characterization of ligand-receptor binding interface with residue-level resolution","pmids":["29135326"],"is_preprint":false},{"year":2018,"finding":"Anti-TL1A antibody C03V binds the TL1A epitope encompassing residue R32, which is critical for TL1A-DR3 but not TL1A-DcR3 binding, explaining why it inhibits TL1A-DR3 interaction more potently than TL1A-DcR3 interaction.","method":"Antibody binding assays, DR3/DcR3 competitive binding assays, epitope mapping, in vitro potency assays, colitis and asthma mouse models","journal":"mAbs","confidence":"High","confidence_rationale":"Tier 1–2 — epitope-function relationship defined biochemically and validated in disease models","pmids":["29436901"],"is_preprint":false},{"year":2018,"finding":"Antimitotic chemotherapeutic agents (taxol, vinblastine) induce lysosome-dependent secretion of TL1A, which engages DR3 to stimulate formation of a FADD- and caspase-8-containing DISC, activating apoptosis. DR3 and TL1A expression levels correlate with apoptotic response to antimitotic drugs in tumor xenografts.","method":"Cell death assays with spindle poisons, lysosomal secretion pathway analysis, DISC complex pull-down, DR3 KO cell lines, xenograft models","journal":"Cell research","confidence":"High","confidence_rationale":"Tier 1–2 — DISC biochemistry combined with genetic KO and in vivo validation","pmids":["29497138"],"is_preprint":false},{"year":2020,"finding":"Autocrine/paracrine TNFSF15:DR3 interactions in human macrophages promote antimicrobial pathways including pyruvate dehydrogenase kinase 1-dependent bacterial uptake, reactive oxygen species, NOS2, and autophagy. The TRAF2/RIP1/RIP3 pathway is required for NF-κB/MAPK activation and antimicrobial induction; the FADD/MALT-1/caspase-8 pathway is required for cytokine secretion but less prominent in bacterial clearance.","method":"siRNA knockdown, pathway inhibitors, bacterial uptake and clearance assays, flow cytometry, ELISA, genotype stratification of risk carriers","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal mechanistic approaches with disease-risk genotype validation","pmids":["32827707"],"is_preprint":false},{"year":2020,"finding":"Direct TL1A signaling via DR3 on collagen-expressing fibroblasts (Col1a2+ cells) promotes intestinal fibrosis in vivo. RNA-sequencing of TL1A-stimulated fibroblasts identified Rho signal transduction as a major downstream pathway; Rho pathway inhibition attenuates TL1A-mediated fibroblast migration and activation.","method":"Rag-/- Dr3∆Col1a2 conditional KO mice, T cell transfer colitis, collagen deposition measurement, RNA-sequencing, Rho pathway inhibition","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional KO with RNA-seq pathway identification and pharmacological validation","pmids":["33097818"],"is_preprint":false},{"year":2010,"finding":"Two isoforms of TL1A with distinct functional activities are generated by differential ectodomain shedding: TL1A(L72-L251) promotes T cell activation, while a novel shorter fragment TL1A(V84-L251) induces growth arrest and apoptosis in endothelial cells. TL1A overexpression induces premature senescence in endothelial progenitor cells.","method":"TL1A isoform characterization in HUVECs and EPCs, overexpression experiments, senescence assays, apoptosis assays","journal":"The journals of gerontology","confidence":"Medium","confidence_rationale":"Tier 2–3 — novel isoform identification with functional differentiation, single lab study","pmids":["20675618"],"is_preprint":false},{"year":2024,"finding":"TL1A is constitutively expressed in alveolar epithelial cells (basal cells) and acts as an epithelial alarmin that cooperates synergistically with IL-33 to induce a transient IL-9high GATA3low 'ILC9' phenotype in lung ILC2s, driving IL-5-dependent allergic airway inflammation.","method":"Large-scale proteomics, lung intravital microscopy, adoptive ILC9 transfer, mouse allergic airway models, human airway biopsy analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including proteomics, intravital imaging, and adoptive transfer with defined mechanistic outcomes","pmids":["38597952"],"is_preprint":false},{"year":2009,"finding":"TLR8 (or TLR7/8) activation potently inhibits FcγR/immune complex-induced TL1A expression in monocytes in a dose-dependent manner, resulting in inhibition of IFN-γ production by co-cultured CD4+ T cells. This suppression is independent of IFN-α.","method":"TLR ligand stimulation, TL1A mRNA and protein measurement, T cell co-culture IFN-γ assay, IFN-α neutralization","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — defined pathway cross-talk with pathway-specific inhibition and control experiments","pmids":["19637197"],"is_preprint":false}],"current_model":"TNFSF15 (TL1A) is a TNF superfamily cytokine that exists as membrane-bound and soluble (shed) forms and functions as the sole ligand for death receptor DR3 (TNFRSF25) and decoy receptor DcR3; DR3 engagement recruits TRADD/TRAF2/RIP to activate NF-κB, MAPK, and PI3K/Akt pathways, with NF-κB-dependent c-IAP2 upregulation preventing apoptosis in certain contexts while caspase-8/FADD-containing DISC formation mediates apoptosis in others; TL1A costimulates diverse lymphocyte subsets (Th1, Th17, Th9, ILC2, NK, Treg, and plasma cells) in a DR3-dependent manner, promotes intestinal fibrosis through direct DR3 signaling on fibroblasts via Rho pathway activation, inhibits angiogenesis and vasculogenesis by inducing endothelial cell apoptosis and shifting VEGFR1 isoform balance toward sFlt1, and suppresses VEGF production via JNK-GATA3-miR-29b signaling; TL1A expression is induced in APCs by FcγR/immune complex signaling and microbial stimuli via TLR-p38 MAPK-NF-κB, and disease-risk SNPs create NF-1 binding sites that increase TNFSF15 transcription, amplifying PRR-induced inflammatory and antimicrobial outcomes."},"narrative":{"teleology":[{"year":2002,"claim":"The identification of TL1A as the ligand for DR3 and decoy receptor DcR3 established the fundamental receptor-ligand axis, demonstrating that DR3 engagement activates NF-κB, induces apoptosis, and costimulates T cell cytokine production.","evidence":"Receptor-ligand binding assays, NF-κB reporter assays, apoptosis assays, and T cell functional assays in vitro and in vivo","pmids":["11911831"],"confidence":"High","gaps":["Downstream signaling intermediates between DR3 and NF-κB/apoptosis not yet defined","In vivo physiological role of TL1A not established","Mechanism of DcR3 decoy function unclear"]},{"year":2003,"claim":"Defining the DR3 proximal signaling complex (TRADD/TRAF2/RIP) and its bifurcation into NF-κB-mediated survival (via c-IAP2) versus apoptosis resolved how TL1A-DR3 signaling produces opposing cell fate outcomes.","evidence":"Co-immunoprecipitation, NF-κB reporter assays, MAPK inhibitors, siRNA knockdown of c-IAP2, apoptosis assays in TF-1 cells","pmids":["12882979"],"confidence":"High","gaps":["Whether FADD/caspase-8 DISC forms downstream of DR3 not yet shown","Signaling in primary immune cells not addressed","Context-dependent fate decision mechanism not resolved"]},{"year":2004,"claim":"Demonstration that TL1A synergizes with IL-12/IL-18 to amplify IFN-γ from T cells and NK cells, and that TL1A exerts angiostatic effects by inducing DR3-dependent endothelial cell apoptosis, revealed TL1A as both a lymphocyte costimulator and anti-angiogenic factor.","evidence":"Cytokine stimulation and intracellular staining of T/NK cells; endothelial cell proliferation, migration, tube formation, and in vivo neovascularization assays with neutralizing antibodies","pmids":["15153521","14871847"],"confidence":"High","gaps":["In vivo role of TL1A in angiogenesis regulation not tested genetically","Whether TL1A costimulation extends to Th17 or other T cell subsets unknown","Mechanism of endothelial apoptosis downstream of DR3 not defined"]},{"year":2007,"claim":"Identification of FcγR/immune complex signaling as the primary inducer of TL1A in monocytes and dendritic cells established how adaptive immune responses generate TL1A to amplify T cell activation.","evidence":"Stimulation of monocytes/DCs with FcγR and TLR agonists, surface and secreted TL1A detection, T cell co-culture","pmids":["17371957"],"confidence":"High","gaps":["Role of TLR pathways in TL1A induction debated (later resolved)","Regulation of membrane-bound versus soluble TL1A not addressed","Whether FcγR-induced TL1A is relevant in vivo not shown"]},{"year":2008,"claim":"TL1A knockout mice and anti-TL1A neutralizing antibodies demonstrated that TL1A-DR3 signaling costimulates both Th1 and Th17 responses in vivo and is required for full disease severity in EAE and chronic colitis, establishing TL1A as a therapeutic target in autoimmune inflammation.","evidence":"TL1A KO mice in EAE; anti-TL1A antibody in DSS chronic colitis and T cell transfer colitis; Th17 differentiation and cytokine assays","pmids":["18411337","18598698"],"confidence":"High","gaps":["Direct effects on fibroblasts and non-immune cells not yet explored","Whether TL1A acts on innate lymphoid cells unknown","Context-dependent Th17-inhibitory effects of TL1A not yet described"]},{"year":2009,"claim":"Crystal structure of TL1A revealed the TNF jelly-roll fold and defined the DR3/DcR3 binding interface, while parallel studies showed TL1A induces DR3-dependent apoptosis of differentiated endothelial progenitor cells and that bacterial stimuli induce TL1A via TLR-p38-NF-κB signaling in APCs.","evidence":"X-ray crystallography at 2.5 Å with mutagenesis; EPC differentiation/apoptosis assays with DR3 neutralization; bacterial stimulation of monocytes/DCs with kinase inhibitors","pmids":["19522538","19329781","19839006"],"confidence":"High","gaps":["Full TL1A-DR3 co-crystal structure not available","Mechanism of stage-specific DR3 expression on EPCs unknown","Cross-regulation between FcγR and TLR pathways for TL1A induction only partially addressed"]},{"year":2010,"claim":"Transgenic constitutive TL1A expression demonstrated sufficiency for IL-13-dependent intestinal inflammation and Treg suppression, while studies of membrane-bound TL1A and differentially shed isoforms showed that distinct TL1A forms have different functional activities on T cells versus endothelial cells.","evidence":"TL1A transgenic mice (T cell and DC-specific); membrane-bound TL1A co-culture assays; TL1A isoform characterization in HUVECs/EPCs","pmids":["20980995","20403353","20826539","20675618"],"confidence":"High","gaps":["Whether TL1A isoforms are differentially regulated in vivo unclear","Direct fibrotic mechanism not yet defined","Context-dependent effects on naive versus committed Th17 cells require further dissection"]},{"year":2013,"claim":"TL1A was shown to act on multiple previously unrecognized DR3-expressing target cells — ILC2s, Tregs, plasma cells, and fibroblasts — revealing breadth as a costimulatory and pro-fibrotic cytokine, and to inhibit vasculogenesis by shifting VEGFR1 splicing toward soluble sFlt1 via Jmjd6 downregulation.","evidence":"DR3 KO and TL1A transgenic mice in allergic and colitis models; TL1A-Ig fusion for Treg expansion; TL1A KO in CIA with plasma cell survival assays; EPC/Matrigel assays with siRNA and splicing analysis; fibroblast TL1A stimulation with DR3 KO","pmids":["24368564","23319737","24140642","23918400","24850426"],"confidence":"High","gaps":["Whether ILC2/Treg/plasma cell effects are interdependent in vivo not resolved","Precise mechanism linking TL1A to Jmjd6 downregulation unknown","Relative contribution of immune versus stromal DR3 signaling to fibrosis not quantified"]},{"year":2014,"claim":"Mechanistic dissection in macrophages revealed that TACE cleaves membrane TL1A to generate soluble TL1A that drives autocrine TRADD/FADD/MALT-1/caspase-8-dependent IL-1 secretion, and that the rs6478108 IBD-risk allele increases TNFSF15 expression, providing a gain-of-function mechanism for disease susceptibility.","evidence":"Human macrophage stimulation with TACE/caspase-8 inhibitors, siRNA knockdown, risk allele genotyping; DR3 siRNA in endothelial apoptosis assays","pmids":["25197060","25161149"],"confidence":"High","gaps":["Whether TACE is the sole sheddase for TL1A not confirmed","Relative contributions of autocrine versus paracrine TL1A in vivo unknown","Full signaling cascade from risk allele to disease phenotype not mapped"]},{"year":2015,"claim":"The disease-risk SNP rs4979462 was shown to create a novel NF-1 binding site that increases TNFSF15 transcription, and biochemical studies demonstrated that soluble TL1A trimers are sufficient to activate DR3 signaling without secondary oligomerization, distinguishing TL1A from TRAIL.","evidence":"Luciferase reporters, EMSA with supershift for NF-1, genotype-stratified mRNA/protein quantification; recombinant soluble TL1A signaling and receptor internalization assays","pmids":["25899471","26509650"],"confidence":"High","gaps":["Whether other disease-risk variants also alter transcription factor binding not systematically tested","Structural basis for why TL1A trimers are sufficient (unlike TRAIL) not resolved at atomic level"]},{"year":2016,"claim":"A JNK→GATA3→miR-29b pathway was identified as the mechanism by which TL1A suppresses VEGF production in endothelial cells, connecting TL1A anti-angiogenic activity to post-transcriptional gene regulation.","evidence":"JNK inhibitor, GATA3 siRNA, miR-29b measurement, VEGF 3′-UTR reporter assays, DR3 siRNA","pmids":["27589684"],"confidence":"High","gaps":["In vivo relevance of miR-29b-mediated VEGF suppression not tested","Whether this pathway operates in non-endothelial cells unknown"]},{"year":2017,"claim":"Epitope mapping by HDX-MS defined the discontinuous TL1A surface recognized by neutralizing antibodies, centering on R32 as critical for DR3 but not DcR3 binding, providing the structural rationale for selective therapeutic blockade.","evidence":"Hydrogen/deuterium exchange MS, computational modeling, competitive binding assays with DR3/DcR3 in vitro and in colitis/asthma models","pmids":["29135326","29436901"],"confidence":"High","gaps":["Full TL1A-DR3 co-crystal structure still lacking","Whether R32-targeting antibodies affect all TL1A functions equally not tested"]},{"year":2018,"claim":"Discovery that antimitotic drugs induce lysosome-dependent TL1A secretion, which then engages DR3 to form a FADD/caspase-8 DISC and trigger apoptosis, established a non-immune role for TL1A-DR3 in chemotherapy-induced tumor cell death.","evidence":"Cell death assays with taxol/vinblastine, lysosomal secretion analysis, DISC pull-down, DR3 KO cell lines, xenograft models","pmids":["29497138"],"confidence":"High","gaps":["Whether TL1A-DR3 mediates clinical antimitotic drug responses in patients unknown","Lysosomal secretion mechanism for TL1A not fully characterized"]},{"year":2020,"claim":"Autocrine TL1A-DR3 signaling in macrophages was shown to promote antimicrobial functions including bacterial uptake, ROS, NOS2, and autophagy through TRAF2/RIP1/RIP3, while conditional DR3 deletion in fibroblasts confirmed that direct TL1A-DR3 signaling drives intestinal fibrosis via Rho pathway activation.","evidence":"siRNA/inhibitor studies with bacterial clearance assays and genotype stratification; cell-type-specific DR3 conditional KO mice, RNA-seq, Rho inhibition","pmids":["32827707","33097818"],"confidence":"High","gaps":["Whether antimicrobial and fibrotic TL1A pathways interact in IBD not addressed","Specific Rho GTPase family members mediating fibrosis not identified"]},{"year":2024,"claim":"TL1A was identified as a constitutively expressed epithelial alarmin in airway basal cells that synergizes with IL-33 to drive a transient IL-9-high ILC9 phenotype, expanding TL1A biology beyond immune cell-derived costimulation to epithelial-innate lymphoid cell crosstalk.","evidence":"Large-scale proteomics, lung intravital microscopy, adoptive ILC9 transfer, mouse allergic airway models, human airway biopsy analysis","pmids":["38597952"],"confidence":"High","gaps":["Mechanism of constitutive TL1A expression in epithelial cells not defined","Whether ILC9 phenotype is relevant in intestinal or other tissue contexts unknown","Relationship between epithelial TL1A and APC-derived TL1A in allergic disease not resolved"]},{"year":null,"claim":"Key unresolved questions include the full atomic structure of the TL1A-DR3 signaling complex, the mechanisms determining whether DR3 engagement triggers survival versus apoptosis in different cell types, the identity of the sheddases and their regulation in vivo, and whether therapeutic TL1A blockade can selectively modulate pathogenic without suppressing protective antimicrobial functions.","evidence":"","pmids":[],"confidence":"High","gaps":["No TL1A-DR3 co-crystal structure available","Cell-type-specific fate decision mechanism unresolved","In vivo sheddase regulation unknown","Selective therapeutic window between pathogenic and protective TL1A functions not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,5,6,22]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[3,8,24,25]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,12,20,31]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,20,22,28,31]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[28]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,18,20,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,5,6,10,14,15,32]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,3,8,21,28]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[24,8]}],"complexes":[],"partners":["TNFRSF25","TNFRSF6B","TRADD","TRAF2","RIPK1","FADD","CASP8","MALT1"],"other_free_text":[]},"mechanistic_narrative":"TNFSF15 (TL1A) is a TNF superfamily cytokine that functions as a pleiotropic immune regulator, anti-angiogenic factor, and pro-fibrotic mediator through engagement of its signaling receptor DR3 (TNFRSF25) and decoy receptor DcR3. Binding to DR3 recruits TRADD, TRAF2, and RIP to activate NF-κB, MAPK (ERK/JNK/p38), and PI3K/Akt pathways, with NF-κB-dependent c-IAP2 upregulation preventing apoptosis in some contexts while FADD/caspase-8-containing DISC formation mediates apoptosis in others [PMID:12882979, PMID:29497138]. TL1A costimulates Th1, Th17, ILC2, NK cell, Treg, and plasma cell responses in a DR3-dependent manner, synergizing with cytokines such as IL-12, IL-18, IL-23, and IL-33 to amplify effector functions including IFN-γ, IL-17, IL-13, and IL-9 production, while also driving intestinal fibrosis through direct Rho pathway activation in DR3-expressing fibroblasts [PMID:15153521, PMID:18411337, PMID:24368564, PMID:38597952, PMID:24140642, PMID:33097818]. TL1A expression in antigen-presenting cells is induced by FcγR/immune complex signaling and microbial TLR-p38 MAPK-NF-κB pathways, and disease-risk SNPs create NF-1 binding sites that increase TNFSF15 transcription, amplifying PRR-induced inflammatory and antimicrobial outcomes including ROS, NOS2, and autophagy [PMID:17371957, PMID:19839006, PMID:25899471, PMID:32827707]."},"prefetch_data":{"uniprot":{"accession":"O95150","full_name":"Tumor necrosis factor ligand superfamily member 15","aliases":["TNF ligand-related molecule 1","Vascular endothelial cell growth inhibitor"],"length_aa":251,"mass_kda":28.1,"function":"Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O95150/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFSF15","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFSF15","total_profiled":1310},"omim":[{"mim_id":"612259","title":"INFLAMMATORY BOWEL DISEASE 16; IBD16","url":"https://www.omim.org/entry/612259"},{"mim_id":"609888","title":"LEPROSY, SUSCEPTIBILITY TO, 1; LPRS1","url":"https://www.omim.org/entry/609888"},{"mim_id":"604052","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 15; TNFSF15","url":"https://www.omim.org/entry/604052"},{"mim_id":"603500","title":"TUMOR NECROSIS FACTOR RECEPTOR 1-ASSOCIATED DEATH DOMAIN PROTEIN; TRADD","url":"https://www.omim.org/entry/603500"},{"mim_id":"603366","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 25; TNFRSF25","url":"https://www.omim.org/entry/603366"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nuclear membrane","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":8.9}],"url":"https://www.proteinatlas.org/search/TNFSF15"},"hgnc":{"alias_symbol":["TL1","VEGI","TL1A","VEGI192A","MGC129934","MGC129935"],"prev_symbol":[]},"alphafold":{"accession":"O95150","domains":[{"cath_id":"2.60.120.40","chopping":"95-249","consensus_level":"high","plddt":92.7737,"start":95,"end":249}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95150","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95150-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95150-F1-predicted_aligned_error_v6.png","plddt_mean":81.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFSF15","jax_strain_url":"https://www.jax.org/strain/search?query=TNFSF15"},"sequence":{"accession":"O95150","fasta_url":"https://rest.uniprot.org/uniprotkb/O95150.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95150/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95150"}},"corpus_meta":[{"pmid":"11911831","id":"PMC_11911831","title":"TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11911831","citation_count":523,"is_preprint":false},{"pmid":"16221758","id":"PMC_16221758","title":"Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16221758","citation_count":376,"is_preprint":false},{"pmid":"14568967","id":"PMC_14568967","title":"Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14568967","citation_count":258,"is_preprint":false},{"pmid":"18598698","id":"PMC_18598698","title":"TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.","date":"2008","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18598698","citation_count":214,"is_preprint":false},{"pmid":"23000144","id":"PMC_23000144","title":"Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23000144","citation_count":213,"is_preprint":false},{"pmid":"18411337","id":"PMC_18411337","title":"TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18411337","citation_count":187,"is_preprint":false},{"pmid":"16698931","id":"PMC_16698931","title":"Role of TL1A and its receptor DR3 in two models of chronic murine ileitis.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16698931","citation_count":137,"is_preprint":false},{"pmid":"17371957","id":"PMC_17371957","title":"The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17371957","citation_count":129,"is_preprint":false},{"pmid":"22684480","id":"PMC_22684480","title":"Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα.","date":"2012","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22684480","citation_count":127,"is_preprint":false},{"pmid":"24368564","id":"PMC_24368564","title":"The TNF-family cytokine TL1A promotes allergic immunopathology through group 2 innate lymphoid cells.","date":"2013","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24368564","citation_count":126,"is_preprint":false},{"pmid":"15153521","id":"PMC_15153521","title":"TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15153521","citation_count":123,"is_preprint":false},{"pmid":"20980995","id":"PMC_20980995","title":"The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.","date":"2010","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20980995","citation_count":122,"is_preprint":false},{"pmid":"12882979","id":"PMC_12882979","title":"TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12882979","citation_count":105,"is_preprint":false},{"pmid":"14871847","id":"PMC_14871847","title":"Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14871847","citation_count":96,"is_preprint":false},{"pmid":"18757243","id":"PMC_18757243","title":"Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.","date":"2008","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/18757243","citation_count":95,"is_preprint":false},{"pmid":"21636646","id":"PMC_21636646","title":"Association of TNFSF15 polymorphism with irritable bowel syndrome.","date":"2011","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/21636646","citation_count":94,"is_preprint":false},{"pmid":"30972074","id":"PMC_30972074","title":"TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30972074","citation_count":92,"is_preprint":false},{"pmid":"29988118","id":"PMC_29988118","title":"Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.","date":"2018","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29988118","citation_count":89,"is_preprint":false},{"pmid":"24850426","id":"PMC_24850426","title":"Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.","date":"2014","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24850426","citation_count":89,"is_preprint":false},{"pmid":"17663424","id":"PMC_17663424","title":"TNFSF15 is an ethnic-specific IBD gene.","date":"2007","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17663424","citation_count":80,"is_preprint":false},{"pmid":"34126262","id":"PMC_34126262","title":"Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.","date":"2021","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/34126262","citation_count":78,"is_preprint":false},{"pmid":"18422820","id":"PMC_18422820","title":"Association of TNFSF15 with Crohn's disease in Koreans.","date":"2008","source":"The American journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18422820","citation_count":78,"is_preprint":false},{"pmid":"26080076","id":"PMC_26080076","title":"VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-κB signaling pathway in experimental traumatic brain injury.","date":"2015","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/26080076","citation_count":76,"is_preprint":false},{"pmid":"19839006","id":"PMC_19839006","title":"Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19839006","citation_count":75,"is_preprint":false},{"pmid":"10360832","id":"PMC_10360832","title":"Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10360832","citation_count":75,"is_preprint":false},{"pmid":"15760679","id":"PMC_15760679","title":"Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15760679","citation_count":71,"is_preprint":false},{"pmid":"18287561","id":"PMC_18287561","title":"TL1A both promotes and protects from renal inflammation and injury.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/18287561","citation_count":65,"is_preprint":false},{"pmid":"21724600","id":"PMC_21724600","title":"Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria.","date":"2011","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/21724600","citation_count":65,"is_preprint":false},{"pmid":"21217782","id":"PMC_21217782","title":"LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21217782","citation_count":64,"is_preprint":false},{"pmid":"26188076","id":"PMC_26188076","title":"The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26188076","citation_count":61,"is_preprint":false},{"pmid":"25197060","id":"PMC_25197060","title":"A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25197060","citation_count":61,"is_preprint":false},{"pmid":"18338776","id":"PMC_18338776","title":"Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population.","date":"2008","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18338776","citation_count":61,"is_preprint":false},{"pmid":"16061878","id":"PMC_16061878","title":"VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth.","date":"2005","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/16061878","citation_count":60,"is_preprint":false},{"pmid":"24453414","id":"PMC_24453414","title":"The role of TL1A and DR3 in autoimmune and inflammatory diseases.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24453414","citation_count":59,"is_preprint":false},{"pmid":"24814505","id":"PMC_24814505","title":"The TNFSF15 gene single nucleotide polymorphism rs7848647 is associated with surgical diverticulitis.","date":"2014","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/24814505","citation_count":59,"is_preprint":false},{"pmid":"35911746","id":"PMC_35911746","title":"Role of TL1A in Inflammatory Autoimmune Diseases: A Comprehensive Review.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35911746","citation_count":58,"is_preprint":false},{"pmid":"19329781","id":"PMC_19329781","title":"Inhibition of endothelial progenitor cell differentiation by VEGI.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19329781","citation_count":56,"is_preprint":false},{"pmid":"32584596","id":"PMC_32584596","title":"The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma.","date":"2020","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32584596","citation_count":53,"is_preprint":false},{"pmid":"22833050","id":"PMC_22833050","title":"TNFSF15 Modulates Neovascularization and Inflammation.","date":"2012","source":"Cancer microenvironment : official journal of the International Cancer Microenvironment Society","url":"https://pubmed.ncbi.nlm.nih.gov/22833050","citation_count":47,"is_preprint":false},{"pmid":"23918400","id":"PMC_23918400","title":"TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23918400","citation_count":47,"is_preprint":false},{"pmid":"20826539","id":"PMC_20826539","title":"Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.","date":"2010","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/20826539","citation_count":46,"is_preprint":false},{"pmid":"32554042","id":"PMC_32554042","title":"Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome.","date":"2020","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/32554042","citation_count":46,"is_preprint":false},{"pmid":"6211393","id":"PMC_6211393","title":"Antitermination and termination functions of the cloned nutL, N, and tL1 modules of coliphage lambda.","date":"1981","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/6211393","citation_count":46,"is_preprint":false},{"pmid":"22210436","id":"PMC_22210436","title":"Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.","date":"2011","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22210436","citation_count":45,"is_preprint":false},{"pmid":"29436901","id":"PMC_29436901","title":"An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease.","date":"2018","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/29436901","citation_count":44,"is_preprint":false},{"pmid":"19918267","id":"PMC_19918267","title":"VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis.","date":"2009","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19918267","citation_count":44,"is_preprint":false},{"pmid":"19543369","id":"PMC_19543369","title":"Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19543369","citation_count":44,"is_preprint":false},{"pmid":"28973304","id":"PMC_28973304","title":"Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28973304","citation_count":42,"is_preprint":false},{"pmid":"29135326","id":"PMC_29135326","title":"Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction.","date":"2017","source":"mAbs","url":"https://pubmed.ncbi.nlm.nih.gov/29135326","citation_count":42,"is_preprint":false},{"pmid":"23319737","id":"PMC_23319737","title":"Cloning, expression, and functional characterization of TL1A-Ig.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23319737","citation_count":42,"is_preprint":false},{"pmid":"25887448","id":"PMC_25887448","title":"The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.","date":"2015","source":"Seminars in arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/25887448","citation_count":39,"is_preprint":false},{"pmid":"23638306","id":"PMC_23638306","title":"SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS.","date":"2013","source":"European journal of microbiology & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23638306","citation_count":39,"is_preprint":false},{"pmid":"34257516","id":"PMC_34257516","title":"Effect and Mechanism of TL1A Expression on Epithelial-Mesenchymal Transition during Chronic Colitis-Related Intestinal Fibrosis.","date":"2021","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/34257516","citation_count":36,"is_preprint":false},{"pmid":"24242819","id":"PMC_24242819","title":"Immunobiology of TNFSF15 and TNFRSF25.","date":"2013","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/24242819","citation_count":35,"is_preprint":false},{"pmid":"23565196","id":"PMC_23565196","title":"The TNF-family cytokine TL1A inhibits proliferation of human activated B cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23565196","citation_count":35,"is_preprint":false},{"pmid":"21188501","id":"PMC_21188501","title":"Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors.","date":"2010","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21188501","citation_count":34,"is_preprint":false},{"pmid":"39266053","id":"PMC_39266053","title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.","date":"2025","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/39266053","citation_count":33,"is_preprint":false},{"pmid":"32958689","id":"PMC_32958689","title":"TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32958689","citation_count":33,"is_preprint":false},{"pmid":"19522538","id":"PMC_19522538","title":"Biochemical and structural characterization of the human TL1A ectodomain.","date":"2009","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19522538","citation_count":33,"is_preprint":false},{"pmid":"33097818","id":"PMC_33097818","title":"Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33097818","citation_count":31,"is_preprint":false},{"pmid":"29497138","id":"PMC_29497138","title":"Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells.","date":"2018","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29497138","citation_count":31,"is_preprint":false},{"pmid":"30949903","id":"PMC_30949903","title":"Effects and Mechanism of Constitutive TL1A Expression on Intestinal Mucosal Barrier in DSS-Induced Colitis.","date":"2019","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30949903","citation_count":30,"is_preprint":false},{"pmid":"20349123","id":"PMC_20349123","title":"TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets.","date":"2010","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20349123","citation_count":29,"is_preprint":false},{"pmid":"27589684","id":"PMC_27589684","title":"TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression via activation of JNK-GATA3 signals.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27589684","citation_count":28,"is_preprint":false},{"pmid":"25404161","id":"PMC_25404161","title":"TL1A regulates TCRγδ+ intraepithelial lymphocytes and gut microbial composition.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25404161","citation_count":28,"is_preprint":false},{"pmid":"26509650","id":"PMC_26509650","title":"Soluble TL1A is sufficient for activation of death receptor 3.","date":"2015","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/26509650","citation_count":28,"is_preprint":false},{"pmid":"15896842","id":"PMC_15896842","title":"Molecular cloning and functional characterizations of chicken TL1A.","date":"2005","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15896842","citation_count":28,"is_preprint":false},{"pmid":"17349692","id":"PMC_17349692","title":"Functional characterization of tumor necrosis factor superfamily 15 (TNFSF15) induced by lipopolysaccharides and Eimeria infection.","date":"2007","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17349692","citation_count":28,"is_preprint":false},{"pmid":"24140642","id":"PMC_24140642","title":"TNF-like ligand 1A (TL1A) gene knockout leads to ameliorated collagen-induced arthritis in mice: implication of TL1A in humoral immune responses.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24140642","citation_count":26,"is_preprint":false},{"pmid":"25899471","id":"PMC_25899471","title":"Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1.","date":"2015","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25899471","citation_count":26,"is_preprint":false},{"pmid":"18523299","id":"PMC_18523299","title":"Role of chicken TL1A on inflammatory responses and partial characterization of its receptor.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18523299","citation_count":26,"is_preprint":false},{"pmid":"19637197","id":"PMC_19637197","title":"TLR8-mediated activation of human monocytes inhibits TL1A expression.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19637197","citation_count":25,"is_preprint":false},{"pmid":"38597952","id":"PMC_38597952","title":"TL1A is an epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation.","date":"2024","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38597952","citation_count":24,"is_preprint":false},{"pmid":"26072972","id":"PMC_26072972","title":"TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients.","date":"2015","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26072972","citation_count":24,"is_preprint":false},{"pmid":"38574740","id":"PMC_38574740","title":"TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.","date":"2024","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38574740","citation_count":23,"is_preprint":false},{"pmid":"24846800","id":"PMC_24846800","title":"Detection rates and phenotypic spectrum of m.3243A>G in the MT-TL1 gene: a molecular diagnostic laboratory perspective.","date":"2014","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/24846800","citation_count":23,"is_preprint":false},{"pmid":"19760077","id":"PMC_19760077","title":"Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760077","citation_count":22,"is_preprint":false},{"pmid":"20675618","id":"PMC_20675618","title":"Two functionally distinct isoforms of TL1A (TNFSF15) generated by differential ectodomain shedding.","date":"2010","source":"The journals of gerontology. Series A, Biological sciences and medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/20675618","citation_count":22,"is_preprint":false},{"pmid":"25161149","id":"PMC_25161149","title":"Death receptor 3 mediates TNFSF15- and TNFα-induced endothelial cell apoptosis.","date":"2014","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25161149","citation_count":22,"is_preprint":false},{"pmid":"32827707","id":"PMC_32827707","title":"TNFSF15 Promotes Antimicrobial Pathways in Human Macrophages and These Are Modulated by TNFSF15 Disease-Risk Variants.","date":"2020","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/32827707","citation_count":21,"is_preprint":false},{"pmid":"28261213","id":"PMC_28261213","title":"Age-Dependent Association of TNFSF15/TNFSF8 Variants and Leprosy Type 1 Reaction.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28261213","citation_count":21,"is_preprint":false},{"pmid":"32732304","id":"PMC_32732304","title":"A TRAIL-TL1A Paracrine Network Involving Adipocytes, Macrophages, and Lymphocytes Induces Adipose Tissue Dysfunction Downstream of E2F1 in Human Obesity.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32732304","citation_count":21,"is_preprint":false},{"pmid":"16517446","id":"PMC_16517446","title":"Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis.","date":"2006","source":"Seminars in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/16517446","citation_count":20,"is_preprint":false},{"pmid":"22348196","id":"PMC_22348196","title":"CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING.","date":"2011","source":"European journal of microbiology & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22348196","citation_count":20,"is_preprint":false},{"pmid":"35255540","id":"PMC_35255540","title":"The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling.","date":"2022","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35255540","citation_count":19,"is_preprint":false},{"pmid":"31379829","id":"PMC_31379829","title":"Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31379829","citation_count":19,"is_preprint":false},{"pmid":"24141405","id":"PMC_24141405","title":"Interferon-γ produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells.","date":"2013","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24141405","citation_count":18,"is_preprint":false},{"pmid":"26200500","id":"PMC_26200500","title":"Association of Genetic Variations in TNFSF15 With Acute Anterior Uveitis in Chinese Han.","date":"2015","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/26200500","citation_count":18,"is_preprint":false},{"pmid":"24783249","id":"PMC_24783249","title":"Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease.","date":"2014","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24783249","citation_count":18,"is_preprint":false},{"pmid":"22388993","id":"PMC_22388993","title":"Advancement in the research on vascular endothelial growth inhibitor (VEGI).","date":"2012","source":"Targeted oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22388993","citation_count":17,"is_preprint":false},{"pmid":"21228792","id":"PMC_21228792","title":"No association between TNFSF15 and IL23R with ulcerative colitis in Koreans.","date":"2011","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21228792","citation_count":17,"is_preprint":false},{"pmid":"26810853","id":"PMC_26810853","title":"Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders.","date":"2016","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26810853","citation_count":17,"is_preprint":false},{"pmid":"31176785","id":"PMC_31176785","title":"TL1A modulates the severity of colitis by promoting Th9 differentiation and IL-9 secretion.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31176785","citation_count":17,"is_preprint":false},{"pmid":"20403353","id":"PMC_20403353","title":"Functional signaling of membrane-bound TL1A induces IFN-gamma expression.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20403353","citation_count":17,"is_preprint":false},{"pmid":"34022066","id":"PMC_34022066","title":"Genome-wide association study identifies TNFSF15 associated with childhood asthma.","date":"2021","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/34022066","citation_count":16,"is_preprint":false},{"pmid":"26936681","id":"PMC_26936681","title":"Downregulation of VEGF and upregulation of TL1A expression induce HUVEC apoptosis in response to high glucose stimuli.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/26936681","citation_count":16,"is_preprint":false},{"pmid":"32381123","id":"PMC_32381123","title":"Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF.","date":"2020","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32381123","citation_count":15,"is_preprint":false},{"pmid":"24416448","id":"PMC_24416448","title":"TL1A induces TCR independent IL-6 and TNF-α production and growth of PLZF⁺ leukocytes.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24416448","citation_count":15,"is_preprint":false},{"pmid":"27507062","id":"PMC_27507062","title":"Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis, Crohn's disease and leprosy.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27507062","citation_count":15,"is_preprint":false},{"pmid":"29748156","id":"PMC_29748156","title":"TL1A mediates fibroblast-like synoviocytes migration and Indian Hedgehog signaling pathway via TNFR2 in patients with rheumatoid arthritis.","date":"2018","source":"European cytokine network","url":"https://pubmed.ncbi.nlm.nih.gov/29748156","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50940,"output_tokens":8044,"usd":0.13674},"stage2":{"model":"claude-opus-4-6","input_tokens":11930,"output_tokens":4595,"usd":0.261788},"total_usd":0.398528,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"TL1A (TNFSF15) is a ligand for death receptor DR3 and decoy receptor TR6/DcR3. Binding to DR3 on T cells induces NF-κB activation and apoptosis in DR3-expressing cell lines, and costimulates T cells to increase IL-2 responsiveness and proinflammatory cytokine secretion. TR6-Fc antagonizes these signaling events.\",\n      \"method\": \"Receptor-ligand binding assays, NF-κB reporter assays, apoptosis assays, T cell functional assays in vitro and in vivo\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — foundational receptor identification with multiple orthogonal functional assays, highly cited original discovery paper\",\n      \"pmids\": [\"11911831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TL1A-DR3 interaction in TF-1 cells induces formation of a signaling complex containing TRADD, TRAF2, and RIP, and activates NF-κB and ERK/JNK/p38 MAPK pathways. NF-κB activation prevents DR3-mediated apoptosis via upregulation of c-IAP2; siRNA knockdown of c-IAP2 sensitizes cells to TL1A-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of signaling complex, NF-κB reporter assays, MAPK inhibitor studies, RNA interference, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including Co-IP, RNAi, and pathway inhibitor rescue in a single study\",\n      \"pmids\": [\"12882979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TL1A synergizes with IL-12 and IL-18 to augment IFN-γ production in human peripheral blood T cells and NK cells. DR3 expression is differentially regulated by IL-12/IL-18 in T cells versus NK cells.\",\n      \"method\": \"Cytokine stimulation assays, intracellular cytokine staining, agonistic anti-DR3 mAb experiments, flow cytometry for DR3 expression\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean functional assays with agonist antibody confirmation, replicated across T cell and NK cell populations\",\n      \"pmids\": [\"15153521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"DcR3 (decoy receptor 3) induces angiogenesis in endothelial cells by neutralizing TL1A, which itself has angiostatic action on endothelial cells expressing DR3. Anti-TL1A and anti-DR3 antibodies mimic DcR3 pro-angiogenic effects, and TL1A promotes HUVEC apoptosis.\",\n      \"method\": \"Endothelial cell proliferation, migration, and tube formation assays; in vivo neovascularization; neutralizing antibody experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal functional assays with antibody-based pathway dissection\",\n      \"pmids\": [\"14871847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TL1A expression in human monocytes and monocyte-derived dendritic cells is strongly induced by FcγR stimulation (immune complexes), but not by TLR agonists. FcγR-induced TL1A appears on the cell surface and in culture medium and enhances T cell responses.\",\n      \"method\": \"TLR and FcγR agonist stimulation, TL1A mRNA and protein detection, surface flow cytometry, T cell co-culture assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — specific pathway identified with multiple stimuli tested across multiple cell types\",\n      \"pmids\": [\"17371957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TL1A-DR3 interaction promotes proliferation and cytokine production from effector Th17 cells. TL1A-deficient dendritic cells have reduced capacity to support Th17 differentiation and proliferation, and TL1A-/- animals display decreased clinical severity in EAE.\",\n      \"method\": \"TL1A knockout mouse generation, EAE model, Th17 differentiation assays, DR3 expression profiling on Th17 cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined cellular phenotype, in vivo and in vitro confirmation\",\n      \"pmids\": [\"18411337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TL1A upregulates both IFN-γ from Th1 cells and IL-17 from Th17 cells in gut-associated lymphoid tissue CD4+ T cells, synergistically with IL-12 and IL-23 respectively. Anti-TL1A antibody prevents and attenuates chronic DSS colitis.\",\n      \"method\": \"DSS chronic colitis model, cytokine measurement, anti-TL1A neutralizing antibody treatment, T-cell transfer colitis model\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo neutralization with defined cytokine readouts in two murine colitis models\",\n      \"pmids\": [\"18598698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Crystal structure of the human TL1A extracellular domain at 2.5 Å resolution reveals a jelly-roll fold typical of the TNF superfamily. Mutagenesis and biochemical characterization define the binding interface with DcR3 and DR3, showing that TL1A-DcR3 interaction differs from other characterized TNF ligand/receptor complexes.\",\n      \"method\": \"X-ray crystallography, mutagenesis, biochemical binding assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and biochemical validation in a single study\",\n      \"pmids\": [\"19522538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VEGI/TNFSF15 inhibits differentiation of endothelial progenitor cells (EPCs) from bone marrow Sca1+ cells. VEGI induces apoptosis of differentiated EPCs but not early-stage EPCs; this is mediated by DR3, which is expressed only on differentiated EPCs. Neutralizing antibodies to DR3 inhibit VEGI-induced apoptosis.\",\n      \"method\": \"EPC differentiation assays, flow cytometry for endothelial markers, apoptosis assays, DR3 neutralizing antibody experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined with receptor-specific neutralization and stage-specific phenotyping\",\n      \"pmids\": [\"19329781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Multiple bacterial species (gram-negative, gram-positive, anaerobes) induce TL1A expression in human APCs (monocytes and DCs) via the TLR signaling pathway; this induction is inhibited by downstream blockade of p38 MAPK and NF-κB activation. Bacterially induced TL1A augments IFN-γ production by CD4+ T cells.\",\n      \"method\": \"Bacterial stimulation of human monocytes/DCs, TL1A mRNA and protein measurement, kinase inhibitor studies, T cell co-culture\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway dissection with inhibitors across multiple bacterial species and cell types\",\n      \"pmids\": [\"19839006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TL1A drives IL-13-dependent small intestinal inflammation when constitutively expressed in T cells or dendritic cells in transgenic mice. TL1A-DR3 interactions are necessary and sufficient for T cell-dependent IBD, and TL1A suppresses inducible Treg generation.\",\n      \"method\": \"Transgenic mouse generation (T cell and DC-specific TL1A expression), TNBS colitis model with TL1A-DR3 blockade, cytokine and histological analysis\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic mouse phenotype with ligand-receptor blockade rescue, multiple disease models\",\n      \"pmids\": [\"20980995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In naive human CD4+ T cells, TL1A via DR3 inhibits Th17 generation, while in committed Th17 cells it supports maintenance of IL-17A expression and proliferation under suboptimal TCR activation. DR3 is induced rapidly upon T cell activation and expressed prominently on IL-17-secreting T cells.\",\n      \"method\": \"Flow cytometry for DR3, Th17 differentiation assays, neutralizing antibodies, DR3-deficient mouse T cells, cytokine measurement\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO cells and neutralizing antibodies with multiple orthogonal readouts\",\n      \"pmids\": [\"20826539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Membrane-bound TL1A (TL1A-M) can bind DR3 through cell-cell contact and induce IFN-γ secretion from IL-12/IL-18-primed CD4+ T cells, demonstrating functional activity of the membrane form distinct from soluble TL1A.\",\n      \"method\": \"TL1A-M expression in HEK-293 cells, DR3-Fc binding assay, T cell co-culture with IFN-γ measurement, anti-TL1A antibody blocking\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct membrane-bound functional assay but single lab, single study\",\n      \"pmids\": [\"20403353\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AMPK activation upregulates LITAF transcription, and LITAF in turn drives TNFSF15 (TL1A) expression by binding to a specific promoter sequence. TNFSF15 inhibits proliferation of prostate cancer cells and endothelial cells, and intratumoral injection reduces tumor size and blood vessel number in vivo.\",\n      \"method\": \"shRNA knockdown, dominant-negative AMPK mutant, promoter binding assay, cell proliferation assays, xenograft tumor model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in single lab defining AMPK-LITAF-TNFSF15 axis\",\n      \"pmids\": [\"21217782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TL1A drives allergic pathology through group 2 innate lymphoid cells (ILC2s), which express surface DR3 and produce IL-13 and type 2 cytokines in response to TL1A. DR3 is required for ILC2 expansion in T cell-dependent and -independent allergic disease models, independent of IL-25 or IL-33.\",\n      \"method\": \"Constitutive TL1A transgenic mice, DR3-deficient mice, ILC2 isolation and functional assays, allergic lung disease models\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and transgenic models with defined cellular phenotype across multiple models\",\n      \"pmids\": [\"24368564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Soluble TL1A-Ig fusion protein mediates rapid in vivo expansion of FoxP3+ regulatory T cells (Tregs) to 30-35% of all CD4+ T cells. Treg expansion requires TCR engagement with MHC class II and is protective against allergic lung inflammation. TL1A-Ig also blocks de novo inducible Treg generation and attenuates Treg suppressive function.\",\n      \"method\": \"TL1A-Ig fusion protein generation, in vivo Treg expansion, TCR-MHC blockade experiments, allergic lung inflammation model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic approaches with defined in vivo cellular and functional outcomes\",\n      \"pmids\": [\"23319737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TL1A signaling via DR3 on primary intestinal myofibroblasts directly increases collagen and IL-31Ra expression. Neutralizing TL1A antibody or DR3 deletion reduces fibroblast and myofibroblast numbers and reverses established colonic fibrosis.\",\n      \"method\": \"Primary myofibroblast culture, TL1A stimulation, anti-TL1A neutralizing antibody, DR3 knockout mice, collagen quantification\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct cell stimulation, genetic KO, and antibody neutralization with multiple fibrosis readouts\",\n      \"pmids\": [\"24850426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TL1A inhibits proliferation of activated human B cells that express DR3 following BCR polyclonal stimulation, without affecting B-cell survival.\",\n      \"method\": \"B cell DR3 expression by flow cytometry and immunofluorescence, B cell proliferation assays with TL1A treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — novel cell type identified with direct functional assay, single lab\",\n      \"pmids\": [\"23565196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFRSF25 (DR3) ligation by TL1A recruits TRAF2 and TRADD in primary T cells and activates NF-κB and PI3K/Akt pathways in a TCR- and IL-2R-dependent manner, leading to constitutive proliferation of CD4+FoxP3+ Tregs through tonic self-antigen exposure.\",\n      \"method\": \"Primary T cell signaling studies, pathway inhibitor assays, Treg proliferation assays\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic signaling dissection in primary cells, single review/research lab synthesis\",\n      \"pmids\": [\"24242819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TL1A KO mice have ameliorated collagen-induced arthritis with reduced anti-collagen antibody titers. Plasma cells (but not B cells) express high levels of DR3 and are direct targets of TL1A; TL1A promotes plasma cell survival and antibody production.\",\n      \"method\": \"TL1A KO mouse generation, CIA model, serum antibody ELISA, DR3 expression on plasma cells by flow cytometry, plasma cell survival assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with in vivo disease model and mechanistic identification of novel TL1A target cell type\",\n      \"pmids\": [\"24140642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TNFSF15:DR3 interactions in human macrophages amplify PRR-induced MAPK/NF-κB/PI3K signaling and cytokine secretion. TACE-induced cleavage of membrane TNFSF15 produces soluble TNFSF15, which then drives TRADD/FADD/MALT-1- and caspase-8-mediated autocrine IL-1 secretion. The rs6478108 disease-risk allele increases TNFSF15 expression, leading to a gain-of-function in PRR signaling.\",\n      \"method\": \"Human macrophage stimulation, TACE inhibitors, caspase-8 inhibitors, siRNA knockdown, TRADD/FADD pathway analysis, risk allele genotyping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal mechanistic approaches including inhibitors, siRNA, and genetic variant functional analysis\",\n      \"pmids\": [\"25197060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"DR3 mediates TNFSF15-induced apoptosis in endothelial cells; DR3 siRNA knockdown confers resistance to TNFSF15-induced apoptosis and is associated with increased ERK1/2 MAPK activity and upregulation of anti-apoptotic c-FLIP and Bcl-2. TNFα-induced upregulation of TNFSF15 is partly responsible for TNFα-induced endothelial cell apoptosis.\",\n      \"method\": \"siRNA knockdown of DR3, apoptosis assays, western blot for c-FLIP and Bcl-2, ERK1/2 activity measurement, TNFSF15 neutralizing antibody\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA-based receptor identification with mechanistic downstream pathway analysis\",\n      \"pmids\": [\"25161149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Soluble TL1A trimers are sufficient to strongly activate DR3-associated pro- and anti-apoptotic signaling pathways without secondary ligand oligomerization, unlike TRAIL death receptors. TL1A-DR3 interaction affinity was measured in a cell-based system, and TL1A induces DR3 internalization.\",\n      \"method\": \"Recombinant soluble TL1A production, cell-based affinity measurement, DR3 signaling assays, receptor internalization assays\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical characterization of ligand requirements with multiple signaling readouts\",\n      \"pmids\": [\"26509650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The PBC-susceptibility allele at rs4979462 in the TNFSF15 locus generates a novel NF-1 binding site that enhances TNFSF15 promoter activity and increases endogenous TNFSF15 protein and mRNA expression.\",\n      \"method\": \"Luciferase reporter assay, electrophoretic mobility shift assay (EMSA), super-shift assay, endogenous mRNA/protein quantification by genotype\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional variant mechanism defined with multiple orthogonal molecular methods\",\n      \"pmids\": [\"25899471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFSF15 inhibits vasculogenesis by simultaneously promoting ubiquitin-mediated degradation of membrane VEGFR1 (mFlt1) and upregulating soluble VEGFR1 (sFlt1) in EPCs, disrupting VEGF/PlGF-induced eNOS and MAPK p38 activation. TNFSF15 also promotes alternative Flt1 pre-mRNA splicing toward sFlt1 by downregulating Jmjd6.\",\n      \"method\": \"EPC culture assays, Matrigel implant in vivo model, siRNA for DR3, Akt/ubiquitin pathway analysis, splicing factor (Jmjd6) knockdown\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic pathway defined in vitro and in vivo with multiple orthogonal approaches\",\n      \"pmids\": [\"23918400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TNFSF15 suppresses VEGF production in endothelial cells by activating the JNK signaling pathway and transcription factor GATA3, which upregulates miR-29b that targets the 3'-UTR of VEGF transcript. siRNA against DR3 or neutralizing antibody against TNFSF15 inhibits miR-29b expression and restores VEGF production.\",\n      \"method\": \"siRNA knockdown, JNK inhibitor (SP600125), miR-29b measurement, 3'-UTR reporter assays, GATA3 siRNA\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic pathway (TNFSF15→JNK→GATA3→miR-29b→VEGF) defined with multiple orthogonal genetic and pharmacological tools\",\n      \"pmids\": [\"27589684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HDX-MS combined with computational modeling revealed that an anti-TL1A monoclonal antibody (mAb1) binds a discontinuous epitope on TL1A spanning the predicted TL1A-DR3 interaction interface, including residue R32 critical for DR3 but not DcR3 binding.\",\n      \"method\": \"Hydrogen/deuterium exchange mass spectrometry, electron-transfer dissociation MS, SASA analysis, computational modeling\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural/biochemical characterization of ligand-receptor binding interface with residue-level resolution\",\n      \"pmids\": [\"29135326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Anti-TL1A antibody C03V binds the TL1A epitope encompassing residue R32, which is critical for TL1A-DR3 but not TL1A-DcR3 binding, explaining why it inhibits TL1A-DR3 interaction more potently than TL1A-DcR3 interaction.\",\n      \"method\": \"Antibody binding assays, DR3/DcR3 competitive binding assays, epitope mapping, in vitro potency assays, colitis and asthma mouse models\",\n      \"journal\": \"mAbs\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — epitope-function relationship defined biochemically and validated in disease models\",\n      \"pmids\": [\"29436901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Antimitotic chemotherapeutic agents (taxol, vinblastine) induce lysosome-dependent secretion of TL1A, which engages DR3 to stimulate formation of a FADD- and caspase-8-containing DISC, activating apoptosis. DR3 and TL1A expression levels correlate with apoptotic response to antimitotic drugs in tumor xenografts.\",\n      \"method\": \"Cell death assays with spindle poisons, lysosomal secretion pathway analysis, DISC complex pull-down, DR3 KO cell lines, xenograft models\",\n      \"journal\": \"Cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — DISC biochemistry combined with genetic KO and in vivo validation\",\n      \"pmids\": [\"29497138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Autocrine/paracrine TNFSF15:DR3 interactions in human macrophages promote antimicrobial pathways including pyruvate dehydrogenase kinase 1-dependent bacterial uptake, reactive oxygen species, NOS2, and autophagy. The TRAF2/RIP1/RIP3 pathway is required for NF-κB/MAPK activation and antimicrobial induction; the FADD/MALT-1/caspase-8 pathway is required for cytokine secretion but less prominent in bacterial clearance.\",\n      \"method\": \"siRNA knockdown, pathway inhibitors, bacterial uptake and clearance assays, flow cytometry, ELISA, genotype stratification of risk carriers\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal mechanistic approaches with disease-risk genotype validation\",\n      \"pmids\": [\"32827707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Direct TL1A signaling via DR3 on collagen-expressing fibroblasts (Col1a2+ cells) promotes intestinal fibrosis in vivo. RNA-sequencing of TL1A-stimulated fibroblasts identified Rho signal transduction as a major downstream pathway; Rho pathway inhibition attenuates TL1A-mediated fibroblast migration and activation.\",\n      \"method\": \"Rag-/- Dr3∆Col1a2 conditional KO mice, T cell transfer colitis, collagen deposition measurement, RNA-sequencing, Rho pathway inhibition\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional KO with RNA-seq pathway identification and pharmacological validation\",\n      \"pmids\": [\"33097818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Two isoforms of TL1A with distinct functional activities are generated by differential ectodomain shedding: TL1A(L72-L251) promotes T cell activation, while a novel shorter fragment TL1A(V84-L251) induces growth arrest and apoptosis in endothelial cells. TL1A overexpression induces premature senescence in endothelial progenitor cells.\",\n      \"method\": \"TL1A isoform characterization in HUVECs and EPCs, overexpression experiments, senescence assays, apoptosis assays\",\n      \"journal\": \"The journals of gerontology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — novel isoform identification with functional differentiation, single lab study\",\n      \"pmids\": [\"20675618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TL1A is constitutively expressed in alveolar epithelial cells (basal cells) and acts as an epithelial alarmin that cooperates synergistically with IL-33 to induce a transient IL-9high GATA3low 'ILC9' phenotype in lung ILC2s, driving IL-5-dependent allergic airway inflammation.\",\n      \"method\": \"Large-scale proteomics, lung intravital microscopy, adoptive ILC9 transfer, mouse allergic airway models, human airway biopsy analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including proteomics, intravital imaging, and adoptive transfer with defined mechanistic outcomes\",\n      \"pmids\": [\"38597952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TLR8 (or TLR7/8) activation potently inhibits FcγR/immune complex-induced TL1A expression in monocytes in a dose-dependent manner, resulting in inhibition of IFN-γ production by co-cultured CD4+ T cells. This suppression is independent of IFN-α.\",\n      \"method\": \"TLR ligand stimulation, TL1A mRNA and protein measurement, T cell co-culture IFN-γ assay, IFN-α neutralization\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined pathway cross-talk with pathway-specific inhibition and control experiments\",\n      \"pmids\": [\"19637197\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFSF15 (TL1A) is a TNF superfamily cytokine that exists as membrane-bound and soluble (shed) forms and functions as the sole ligand for death receptor DR3 (TNFRSF25) and decoy receptor DcR3; DR3 engagement recruits TRADD/TRAF2/RIP to activate NF-κB, MAPK, and PI3K/Akt pathways, with NF-κB-dependent c-IAP2 upregulation preventing apoptosis in certain contexts while caspase-8/FADD-containing DISC formation mediates apoptosis in others; TL1A costimulates diverse lymphocyte subsets (Th1, Th17, Th9, ILC2, NK, Treg, and plasma cells) in a DR3-dependent manner, promotes intestinal fibrosis through direct DR3 signaling on fibroblasts via Rho pathway activation, inhibits angiogenesis and vasculogenesis by inducing endothelial cell apoptosis and shifting VEGFR1 isoform balance toward sFlt1, and suppresses VEGF production via JNK-GATA3-miR-29b signaling; TL1A expression is induced in APCs by FcγR/immune complex signaling and microbial stimuli via TLR-p38 MAPK-NF-κB, and disease-risk SNPs create NF-1 binding sites that increase TNFSF15 transcription, amplifying PRR-induced inflammatory and antimicrobial outcomes.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFSF15 (TL1A) is a TNF superfamily cytokine that functions as a pleiotropic immune regulator, anti-angiogenic factor, and pro-fibrotic mediator through engagement of its signaling receptor DR3 (TNFRSF25) and decoy receptor DcR3. Binding to DR3 recruits TRADD, TRAF2, and RIP to activate NF-κB, MAPK (ERK/JNK/p38), and PI3K/Akt pathways, with NF-κB-dependent c-IAP2 upregulation preventing apoptosis in some contexts while FADD/caspase-8-containing DISC formation mediates apoptosis in others [PMID:12882979, PMID:29497138]. TL1A costimulates Th1, Th17, ILC2, NK cell, Treg, and plasma cell responses in a DR3-dependent manner, synergizing with cytokines such as IL-12, IL-18, IL-23, and IL-33 to amplify effector functions including IFN-γ, IL-17, IL-13, and IL-9 production, while also driving intestinal fibrosis through direct Rho pathway activation in DR3-expressing fibroblasts [PMID:15153521, PMID:18411337, PMID:24368564, PMID:38597952, PMID:24140642, PMID:33097818]. TL1A expression in antigen-presenting cells is induced by FcγR/immune complex signaling and microbial TLR-p38 MAPK-NF-κB pathways, and disease-risk SNPs create NF-1 binding sites that increase TNFSF15 transcription, amplifying PRR-induced inflammatory and antimicrobial outcomes including ROS, NOS2, and autophagy [PMID:17371957, PMID:19839006, PMID:25899471, PMID:32827707].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"The identification of TL1A as the ligand for DR3 and decoy receptor DcR3 established the fundamental receptor-ligand axis, demonstrating that DR3 engagement activates NF-κB, induces apoptosis, and costimulates T cell cytokine production.\",\n      \"evidence\": \"Receptor-ligand binding assays, NF-κB reporter assays, apoptosis assays, and T cell functional assays in vitro and in vivo\",\n      \"pmids\": [\"11911831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling intermediates between DR3 and NF-κB/apoptosis not yet defined\", \"In vivo physiological role of TL1A not established\", \"Mechanism of DcR3 decoy function unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defining the DR3 proximal signaling complex (TRADD/TRAF2/RIP) and its bifurcation into NF-κB-mediated survival (via c-IAP2) versus apoptosis resolved how TL1A-DR3 signaling produces opposing cell fate outcomes.\",\n      \"evidence\": \"Co-immunoprecipitation, NF-κB reporter assays, MAPK inhibitors, siRNA knockdown of c-IAP2, apoptosis assays in TF-1 cells\",\n      \"pmids\": [\"12882979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FADD/caspase-8 DISC forms downstream of DR3 not yet shown\", \"Signaling in primary immune cells not addressed\", \"Context-dependent fate decision mechanism not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstration that TL1A synergizes with IL-12/IL-18 to amplify IFN-γ from T cells and NK cells, and that TL1A exerts angiostatic effects by inducing DR3-dependent endothelial cell apoptosis, revealed TL1A as both a lymphocyte costimulator and anti-angiogenic factor.\",\n      \"evidence\": \"Cytokine stimulation and intracellular staining of T/NK cells; endothelial cell proliferation, migration, tube formation, and in vivo neovascularization assays with neutralizing antibodies\",\n      \"pmids\": [\"15153521\", \"14871847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo role of TL1A in angiogenesis regulation not tested genetically\", \"Whether TL1A costimulation extends to Th17 or other T cell subsets unknown\", \"Mechanism of endothelial apoptosis downstream of DR3 not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of FcγR/immune complex signaling as the primary inducer of TL1A in monocytes and dendritic cells established how adaptive immune responses generate TL1A to amplify T cell activation.\",\n      \"evidence\": \"Stimulation of monocytes/DCs with FcγR and TLR agonists, surface and secreted TL1A detection, T cell co-culture\",\n      \"pmids\": [\"17371957\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of TLR pathways in TL1A induction debated (later resolved)\", \"Regulation of membrane-bound versus soluble TL1A not addressed\", \"Whether FcγR-induced TL1A is relevant in vivo not shown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"TL1A knockout mice and anti-TL1A neutralizing antibodies demonstrated that TL1A-DR3 signaling costimulates both Th1 and Th17 responses in vivo and is required for full disease severity in EAE and chronic colitis, establishing TL1A as a therapeutic target in autoimmune inflammation.\",\n      \"evidence\": \"TL1A KO mice in EAE; anti-TL1A antibody in DSS chronic colitis and T cell transfer colitis; Th17 differentiation and cytokine assays\",\n      \"pmids\": [\"18411337\", \"18598698\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct effects on fibroblasts and non-immune cells not yet explored\", \"Whether TL1A acts on innate lymphoid cells unknown\", \"Context-dependent Th17-inhibitory effects of TL1A not yet described\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Crystal structure of TL1A revealed the TNF jelly-roll fold and defined the DR3/DcR3 binding interface, while parallel studies showed TL1A induces DR3-dependent apoptosis of differentiated endothelial progenitor cells and that bacterial stimuli induce TL1A via TLR-p38-NF-κB signaling in APCs.\",\n      \"evidence\": \"X-ray crystallography at 2.5 Å with mutagenesis; EPC differentiation/apoptosis assays with DR3 neutralization; bacterial stimulation of monocytes/DCs with kinase inhibitors\",\n      \"pmids\": [\"19522538\", \"19329781\", \"19839006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full TL1A-DR3 co-crystal structure not available\", \"Mechanism of stage-specific DR3 expression on EPCs unknown\", \"Cross-regulation between FcγR and TLR pathways for TL1A induction only partially addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Transgenic constitutive TL1A expression demonstrated sufficiency for IL-13-dependent intestinal inflammation and Treg suppression, while studies of membrane-bound TL1A and differentially shed isoforms showed that distinct TL1A forms have different functional activities on T cells versus endothelial cells.\",\n      \"evidence\": \"TL1A transgenic mice (T cell and DC-specific); membrane-bound TL1A co-culture assays; TL1A isoform characterization in HUVECs/EPCs\",\n      \"pmids\": [\"20980995\", \"20403353\", \"20826539\", \"20675618\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TL1A isoforms are differentially regulated in vivo unclear\", \"Direct fibrotic mechanism not yet defined\", \"Context-dependent effects on naive versus committed Th17 cells require further dissection\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"TL1A was shown to act on multiple previously unrecognized DR3-expressing target cells — ILC2s, Tregs, plasma cells, and fibroblasts — revealing breadth as a costimulatory and pro-fibrotic cytokine, and to inhibit vasculogenesis by shifting VEGFR1 splicing toward soluble sFlt1 via Jmjd6 downregulation.\",\n      \"evidence\": \"DR3 KO and TL1A transgenic mice in allergic and colitis models; TL1A-Ig fusion for Treg expansion; TL1A KO in CIA with plasma cell survival assays; EPC/Matrigel assays with siRNA and splicing analysis; fibroblast TL1A stimulation with DR3 KO\",\n      \"pmids\": [\"24368564\", \"23319737\", \"24140642\", \"23918400\", \"24850426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ILC2/Treg/plasma cell effects are interdependent in vivo not resolved\", \"Precise mechanism linking TL1A to Jmjd6 downregulation unknown\", \"Relative contribution of immune versus stromal DR3 signaling to fibrosis not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mechanistic dissection in macrophages revealed that TACE cleaves membrane TL1A to generate soluble TL1A that drives autocrine TRADD/FADD/MALT-1/caspase-8-dependent IL-1 secretion, and that the rs6478108 IBD-risk allele increases TNFSF15 expression, providing a gain-of-function mechanism for disease susceptibility.\",\n      \"evidence\": \"Human macrophage stimulation with TACE/caspase-8 inhibitors, siRNA knockdown, risk allele genotyping; DR3 siRNA in endothelial apoptosis assays\",\n      \"pmids\": [\"25197060\", \"25161149\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TACE is the sole sheddase for TL1A not confirmed\", \"Relative contributions of autocrine versus paracrine TL1A in vivo unknown\", \"Full signaling cascade from risk allele to disease phenotype not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The disease-risk SNP rs4979462 was shown to create a novel NF-1 binding site that increases TNFSF15 transcription, and biochemical studies demonstrated that soluble TL1A trimers are sufficient to activate DR3 signaling without secondary oligomerization, distinguishing TL1A from TRAIL.\",\n      \"evidence\": \"Luciferase reporters, EMSA with supershift for NF-1, genotype-stratified mRNA/protein quantification; recombinant soluble TL1A signaling and receptor internalization assays\",\n      \"pmids\": [\"25899471\", \"26509650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other disease-risk variants also alter transcription factor binding not systematically tested\", \"Structural basis for why TL1A trimers are sufficient (unlike TRAIL) not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A JNK→GATA3→miR-29b pathway was identified as the mechanism by which TL1A suppresses VEGF production in endothelial cells, connecting TL1A anti-angiogenic activity to post-transcriptional gene regulation.\",\n      \"evidence\": \"JNK inhibitor, GATA3 siRNA, miR-29b measurement, VEGF 3′-UTR reporter assays, DR3 siRNA\",\n      \"pmids\": [\"27589684\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of miR-29b-mediated VEGF suppression not tested\", \"Whether this pathway operates in non-endothelial cells unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Epitope mapping by HDX-MS defined the discontinuous TL1A surface recognized by neutralizing antibodies, centering on R32 as critical for DR3 but not DcR3 binding, providing the structural rationale for selective therapeutic blockade.\",\n      \"evidence\": \"Hydrogen/deuterium exchange MS, computational modeling, competitive binding assays with DR3/DcR3 in vitro and in colitis/asthma models\",\n      \"pmids\": [\"29135326\", \"29436901\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full TL1A-DR3 co-crystal structure still lacking\", \"Whether R32-targeting antibodies affect all TL1A functions equally not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery that antimitotic drugs induce lysosome-dependent TL1A secretion, which then engages DR3 to form a FADD/caspase-8 DISC and trigger apoptosis, established a non-immune role for TL1A-DR3 in chemotherapy-induced tumor cell death.\",\n      \"evidence\": \"Cell death assays with taxol/vinblastine, lysosomal secretion analysis, DISC pull-down, DR3 KO cell lines, xenograft models\",\n      \"pmids\": [\"29497138\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TL1A-DR3 mediates clinical antimitotic drug responses in patients unknown\", \"Lysosomal secretion mechanism for TL1A not fully characterized\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Autocrine TL1A-DR3 signaling in macrophages was shown to promote antimicrobial functions including bacterial uptake, ROS, NOS2, and autophagy through TRAF2/RIP1/RIP3, while conditional DR3 deletion in fibroblasts confirmed that direct TL1A-DR3 signaling drives intestinal fibrosis via Rho pathway activation.\",\n      \"evidence\": \"siRNA/inhibitor studies with bacterial clearance assays and genotype stratification; cell-type-specific DR3 conditional KO mice, RNA-seq, Rho inhibition\",\n      \"pmids\": [\"32827707\", \"33097818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether antimicrobial and fibrotic TL1A pathways interact in IBD not addressed\", \"Specific Rho GTPase family members mediating fibrosis not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"TL1A was identified as a constitutively expressed epithelial alarmin in airway basal cells that synergizes with IL-33 to drive a transient IL-9-high ILC9 phenotype, expanding TL1A biology beyond immune cell-derived costimulation to epithelial-innate lymphoid cell crosstalk.\",\n      \"evidence\": \"Large-scale proteomics, lung intravital microscopy, adoptive ILC9 transfer, mouse allergic airway models, human airway biopsy analysis\",\n      \"pmids\": [\"38597952\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of constitutive TL1A expression in epithelial cells not defined\", \"Whether ILC9 phenotype is relevant in intestinal or other tissue contexts unknown\", \"Relationship between epithelial TL1A and APC-derived TL1A in allergic disease not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full atomic structure of the TL1A-DR3 signaling complex, the mechanisms determining whether DR3 engagement triggers survival versus apoptosis in different cell types, the identity of the sheddases and their regulation in vivo, and whether therapeutic TL1A blockade can selectively modulate pathogenic without suppressing protective antimicrobial functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No TL1A-DR3 co-crystal structure available\", \"Cell-type-specific fate decision mechanism unresolved\", \"In vivo sheddase regulation unknown\", \"Selective therapeutic window between pathogenic and protective TL1A functions not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 5, 6, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 8, 24, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 12, 20, 31]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 20, 22, 28, 31]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 18, 20, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 5, 6, 10, 14, 15, 32]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 3, 8, 21, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [24, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFRSF25\",\n      \"TNFRSF6B\",\n      \"TRADD\",\n      \"TRAF2\",\n      \"RIPK1\",\n      \"FADD\",\n      \"CASP8\",\n      \"MALT1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}